ECOG Performance Status
Clinical Context & Background
Derived from Physical Ability, Bed/Chair Confinement, and Self-Care capacity.Reference Data
| ECOG Grade | KPS Equivalent | Therapeutic Implications | Physical Capability |
|---|---|---|---|
| 0 | 100 | Standard full-dose treatment generally appropriate | Full active, no restriction |
| 1 | 80 - 90 | Standard full-dose treatment generally appropriate | Restricted strenuous activity, ambulatory |
| 2 | 60 - 70 | Increased toxicity risk; consider dose adjustment | Self-care, no work, <50% in bed |
| 3 | 40 - 50 | Systemic therapy often contraindicated | Limited self-care, >50% in bed |
| 4 | 10 - 30 | Best Supportive Care (BSC) usually recommended | Completely disabled, 100% in bed |
Frequently Asked Questions
What is the ECOG Performance Status scale?
The ECOG Performance Status is a standardized scale developed by the Eastern Cooperative Oncology Group to assess how a cancer patient's disease affects their daily living abilities. It ranges from 0 (fully active) to 4 (completely disabled) and helps clinicians determine appropriate treatment options and prognosis.
How does ECOG score affect cancer treatment decisions?
ECOG performance status directly influences treatment eligibility. Patients with ECOG 0-1 are typically candidates for standard chemotherapy regimens. ECOG 2 patients may receive modified doses, while ECOG 3-4 patients often benefit more from supportive care than aggressive treatment due to increased toxicity risks.
What is the difference between ECOG and Karnofsky Performance Status?
Both scales measure functional status, but ECOG uses 5 grades (0-4) while Karnofsky uses percentages (0-100%). ECOG is simpler and more commonly used in clinical trials. Generally, ECOG 0 = KPS 100%, ECOG 1 = KPS 80-90%, ECOG 2 = KPS 60-70%, ECOG 3 = KPS 40-50%, and ECOG 4 = KPS 10-30%.
Can ECOG performance status change during cancer treatment?
Yes, ECOG status is dynamic and should be reassessed regularly. It may improve with successful treatment or worsen with disease progression or treatment toxicity. Changes in ECOG status often prompt treatment modifications.
Evidence-based oncology decision support. Verify with clinical guidelines.